17 studies found for:    Open Studies | Vascular Diseases | UCSD OR UC San Diego OR VA San Diego
Show Display Options
Rank Status Study
1 Recruiting Post-Market CorPath Registry on the CorPath 200 System in Percutaneous Coronary Interventions
Conditions: Coronary Artery Disease;   Coronary Disease;   Myocardial Ischemia;   Heart Diseases;   Cardiovascular Diseases;   Arteriosclerosis;   Arterial Occlusive Diseases;   Vascular Diseases
Intervention: Procedure: CorPath-assisted Percutaneous Coronary Intervention
2 Recruiting A Complex Contraception Registry
Conditions: Diabetes;   Cardiovascular Disease;   Epilepsy;   Migraine;   Neurological Disorders;   Cancer;   Bariatric Surgery Candidate;   Organ or Tissue Transplant; Complications;   Lupus Erythematosus, Systemic;   Other Hematologic Conditions;   Other Venous Embolism and Thrombosis
Intervention:
3 Recruiting Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System
Condition: Abdominal Aortic Aneurysm (AAA)
Intervention: Device: Nellix System
4 Recruiting CER-001 Atherosclerosis Regression ACS Trial
Condition: Acute Coronary Syndromes
Interventions: Drug: CER-001;   Drug: Placebo
5 Recruiting Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
Conditions: Myeloproliferative Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
6 Available Expanded Access Treatment Protocol CA204-143
Condition: Multiple Myeloma
Intervention: Drug: Elotuzumab
7 Recruiting PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
Condition: Portopulmonary Hypertension
Interventions: Drug: Macitentan;   Other: Placebo
8 Recruiting Post Market Surveillance Study of the Wingspan Stent System
Condition: Intracranial Atherosclerosis
Intervention: Device: Wingspan Stent System
9 Recruiting U.S. CTEPH Registry
Conditions: Chronic Thromboembolic Pulmonary Hypertension (CTEPH);   Pulmonary Hypertension
Intervention:
10 Recruiting Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Condition: Portopulmonary Hypertension
Intervention: Drug: Ambrisentan
11 Recruiting Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
Conditions: Diabetic Retinopathy;   HIV
Interventions: Drug: Tesamorelin;   Drug: Placebo-Control
12 Recruiting Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
13 Recruiting Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Conditions: Stroke, Acute;   Cerebral Infarction
Interventions: Procedure: Endovascular Thrombectomy;   Device: Trevo Retriever;   Device: Solitaire™ FR Revascularization Device;   Device: Penumbra thrombectomy system;   Device: Covidien MindFrame Capture Revascularization Device
14 Recruiting Evaluation of the Duration of Therapy for Thrombosis in Children
Condition: Venous Thrombosis
Interventions: Other: Shortened duration (6 weeks) of anticoagulant therapy;   Other: Conventional duration (3 months) of anticoagulant therapy;   Other: No Intervention
15 Recruiting Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-angle Glaucoma or Ocular Hypertension
Conditions: Glaucoma, Open-Angle;   Ocular Hypertension
Interventions: Drug: Bimatoprost sustained-release;   Other: Sham;   Drug: Timolol;   Drug: Timolol Vehicle (placebo)
16 Recruiting Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Macitentan 10 mg;   Drug: Placebo
17 Recruiting Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Conditions: HIV Infections;   Cardiovascular Diseases
Interventions: Drug: Pitavastatin;   Drug: Placebo

Indicates status has not been verified in more than two years